José Sanfélix-Genovés1, Ferrán Catalá-López2, Gabriel Sanfélix-Gimeno3, Isabel Hurtado3, Cristóbal Baixauli3, Salvador Peiró3. 1. Centro Superior de Investigación en Salud Pública (CSISP) - Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Valencia, España. Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Valencia, España; Fundación de Investigación del Hospital Clínico Universitario-Instituto de Investigación Sanitaria (INCLIVA), Valencia, España. Electronic address: sanfelix_jos@gva.es. 2. Centro Superior de Investigación en Salud Pública (CSISP) - Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Valencia, España. Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Valencia, España; División de Farmacoepidemiología y Farmacovigilancia, Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Madrid, España. 3. Centro Superior de Investigación en Salud Pública (CSISP) - Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Valencia, España. Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Valencia, España.
Abstract
BACKGROUND AND OBJECTIVE: Analysis of the variability in the recommendations of the main guidelines and clinical documents for the management of osteoporosis. MATERIAL AND METHOD: Searches were carried out in PubMed, Google, web pages of national and international scientific societies related to the management of osteoporosis, and agencies that develop guidelines. We analyzed guidelines and clinical documents that included recommendations for the indication of bone densitometry and/or pharmacological treatment, which could influence the management of osteoporosis in the Spanish National Health System, which have been published between 2006 and 2012. RESULTS: We included 12 documents. Eleven recommend performing bone densitometry upon assessing women risk factors, but the number and type of risk factors vary between documents: 6 recommend its implementation to all women over 65 years, 4 in men aged 65-70 years, and 3 when there is radiological suspicion of osteoporosis. There is agreement on the recommendations on the indication for densitometry to monitor drug response. In primary prevention, all national documents combined risk factors and densitometric osteoporosis and 3 of them recommend individual assessment according to risk factors. Most of the international guidelines require the calculation of risk with the FRAX(®) tool. In secondary prevention, all documents recommend treatment in cases of hip or clinical vertebral fracture; in men, and for the rest of fractures, the recommendations are heterogeneous. CONCLUSIONS: Overall there is a high variability in the recommendations of guidelines and other documents for the management of osteoporosis.
BACKGROUND AND OBJECTIVE: Analysis of the variability in the recommendations of the main guidelines and clinical documents for the management of osteoporosis. MATERIAL AND METHOD: Searches were carried out in PubMed, Google, web pages of national and international scientific societies related to the management of osteoporosis, and agencies that develop guidelines. We analyzed guidelines and clinical documents that included recommendations for the indication of bone densitometry and/or pharmacological treatment, which could influence the management of osteoporosis in the Spanish National Health System, which have been published between 2006 and 2012. RESULTS: We included 12 documents. Eleven recommend performing bone densitometry upon assessing women risk factors, but the number and type of risk factors vary between documents: 6 recommend its implementation to all women over 65 years, 4 in men aged 65-70 years, and 3 when there is radiological suspicion of osteoporosis. There is agreement on the recommendations on the indication for densitometry to monitor drug response. In primary prevention, all national documents combined risk factors and densitometric osteoporosis and 3 of them recommend individual assessment according to risk factors. Most of the international guidelines require the calculation of risk with the FRAX(®) tool. In secondary prevention, all documents recommend treatment in cases of hip or clinical vertebral fracture; in men, and for the rest of fractures, the recommendations are heterogeneous. CONCLUSIONS: Overall there is a high variability in the recommendations of guidelines and other documents for the management of osteoporosis.
Authors: Gabriel Sanfélix-Gimeno; Isabel Hurtado; José Sanfélix-Genovés; Cristóbal Baixauli-Pérez; Clara L Rodríguez-Bernal; Salvador Peiró Journal: PLoS One Date: 2015-08-28 Impact factor: 3.240
Authors: Gabriel Sanfélix-Gimeno; Julián Librero-López; Gracia Modroño-Riaño; Salvador Peiró; Clara L Rodríguez-Bernal Journal: Front Pharmacol Date: 2018-04-13 Impact factor: 5.810
Authors: Aníbal García-Sempere; Isabel Hurtado; José Sanfélix-Genovés; Clara L Rodríguez-Bernal; Rafael Gil Orozco; Salvador Peiró; Gabriel Sanfélix-Gimeno Journal: Sci Rep Date: 2017-09-18 Impact factor: 4.379
Authors: Aníbal García-Sempere; Isabel Hurtado; Salvador Peiró; Francisco Sánchez-Sáez; Yared Santaana; Clara Rodríguez-Bernal; Gabriel Sanfélix-Gimeno; José Sanfélix-Genovés Journal: J Clin Med Date: 2022-04-25 Impact factor: 4.241
Authors: Fran Llopis-Cardona; Carmen Armero; Isabel Hurtado; Aníbal García-Sempere; Salvador Peiró; Clara L Rodríguez-Bernal; Gabriel Sanfélix-Gimeno Journal: J Bone Miner Res Date: 2022-05-19 Impact factor: 6.390